Back HCV Treatment

HCV Treatment

AASLD 2014: Sofosbuvir/Ledipasvir Cures Nearly All Genotype 1 HIV/HCV Coinfected Patients

All but 1 participant treated with a coformulation of sofosbuvir and ledipasvir (Harvoni) achieved sustained virological response at 12 weeks post-treatment in a study looking at traditionally hard-to-treat HIV/HCV coinfected patients, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.

alt

Read more:

FDA Approves Simeprevir + Sofosbuvir Combination for Hepatitis C

The U.S. Food and Drug Administration (FDA) this week announced additional approval of interferon-free oral therapy for chronic hepatitis C combining Janssen's HCV protease inhibitor simeprevir (Olysio) plus Gilead Sciences' HCV polymerase inhibitor sofosbuvir (Sovaldi), both of which were approved separately in late 2013.

alt

Read more:

IDWeek 2014: AbbVie 3D HCV Regimen Well-tolerated in PEARL Trials

AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 PEARL trials, according to a pooled analysis presented at IDWeek 2014 last week in Philadelphia. Serious side effects were uncommon and few people discontinued treatment for this reason.

alt

Read more:

AASLD Liver Meeting Starts this Weekend in Boston

The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting gets underway this weekend, running through November 11 at the Hynes Convention Center in Boston. Once again, this year's meeting will highlight interferon-free direct-acting antiviral regimens for hepatitis C.

alt

Read more:

IDWeek 2014: Sofosbuvir/Ledipasvir Safe and Effective for Genotype 1 HCV

A single-tablet regimen containing the hepatitis C virus (HCV) nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir -- the combination in Gilead Science's recently approved Harvoni pill -- was well-tolerated and cured 97% of patients with HCV genotype 1 in the Phase 3 ION trials, researchers reported at the IDWeek 2014 meeting last week in Philadelphia.

alt

Read more: